Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype

Understanding of the genetic mechanisms and identification of the biological markers of tumor progression that form the individual molecular phenotype of transformed cells can characterize the degree of tumor malignancy, the ability to metastasize, the hormonal sensitivity, and the effectiveness of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina K. Ibragimova, Matvey M. Tsyganov, Nikolai V. Litviakov
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	triple-negative breast cancer microarray analysis CNA prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7fe3f71fd8cb471393fb42afb2722aa2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7fe3f71fd8cb471393fb42afb2722aa2
record_format	dspace
spelling	oai:doaj.org-article:7fe3f71fd8cb471393fb42afb2722aa22021-11-11T15:28:51ZMolecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype10.3390/cancers132153482072-6694https://doaj.org/article/7fe3f71fd8cb471393fb42afb2722aa22021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5348https://doaj.org/toc/2072-6694Understanding of the genetic mechanisms and identification of the biological markers of tumor progression that form the individual molecular phenotype of transformed cells can characterize the degree of tumor malignancy, the ability to metastasize, the hormonal sensitivity, and the effectiveness of chemotherapy, etc. Breast cancer (BC) is a genetically heterogeneous disease with different molecular biological and clinical characteristics. The available knowledge about the genetic heterogeneity of the most aggressive molecular subtype of breast cancer—triple-negative (TN)—has led to discoveries in drug treatment, including the use of DNA damaging agents (platinum and PARP inhibitors) for these tumors, as well as the use of immunotherapy. Most importantly, the ability to prescribe optimal drug treatment regimens for patients with TNBC based on knowledge of the molecular-genetic characteristics of this subtype of BC will allow the achievement of high rates of overall and disease-free survival. Thus, identification of the molecular-genetic phenotype of breast cancer is an important prognostic factor of the disease and allows personalization of the patient’s treatment.Marina K. IbragimovaMatvey M. TsyganovNikolai V. LitviakovMDPI AGarticletriple-negative breast cancermicroarray analysisCNAprognosisNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5348, p 5348 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	triple-negative breast cancer microarray analysis CNA prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	triple-negative breast cancer microarray analysis CNA prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Marina K. Ibragimova Matvey M. Tsyganov Nikolai V. Litviakov Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
description	Understanding of the genetic mechanisms and identification of the biological markers of tumor progression that form the individual molecular phenotype of transformed cells can characterize the degree of tumor malignancy, the ability to metastasize, the hormonal sensitivity, and the effectiveness of chemotherapy, etc. Breast cancer (BC) is a genetically heterogeneous disease with different molecular biological and clinical characteristics. The available knowledge about the genetic heterogeneity of the most aggressive molecular subtype of breast cancer—triple-negative (TN)—has led to discoveries in drug treatment, including the use of DNA damaging agents (platinum and PARP inhibitors) for these tumors, as well as the use of immunotherapy. Most importantly, the ability to prescribe optimal drug treatment regimens for patients with TNBC based on knowledge of the molecular-genetic characteristics of this subtype of BC will allow the achievement of high rates of overall and disease-free survival. Thus, identification of the molecular-genetic phenotype of breast cancer is an important prognostic factor of the disease and allows personalization of the patient’s treatment.
format	article
author	Marina K. Ibragimova Matvey M. Tsyganov Nikolai V. Litviakov
author_facet	Marina K. Ibragimova Matvey M. Tsyganov Nikolai V. Litviakov
author_sort	Marina K. Ibragimova
title	Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
title_short	Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
title_full	Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
title_fullStr	Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
title_full_unstemmed	Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
title_sort	molecular-genetic portrait of breast cancer with triple negative phenotype
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/7fe3f71fd8cb471393fb42afb2722aa2
work_keys_str_mv	AT marinakibragimova moleculargeneticportraitofbreastcancerwithtriplenegativephenotype AT matveymtsyganov moleculargeneticportraitofbreastcancerwithtriplenegativephenotype AT nikolaivlitviakov moleculargeneticportraitofbreastcancerwithtriplenegativephenotype
_version_	1718435248543367168

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype

Ejemplares similares